Background We report the results from a first-line phase III randomized clinical trial on
metastatic colorectal cancer (mCRC) aimed at evaluating the effectiveness of adding …

Background Bevacizumab significantly improves survival when added to chemotherapy for
metastatic colorectal cancer (mCRC). The Bevacizumab Expanded Access Trial (BEAT) …

CRA3503 Background: BEV in combination with fluoropyrimidine-based CT is standard
treatment for mCRC in the first-line (1L) and BEV-naïve second-line (2L) settings. This is the …

Purpose. This analysis pooled individual patient data from randomized controlled trials
(RCTs) to more thoroughly examine clinical outcomes when adding bevacizumab to …

Background Although the addition of bevacizumab to 1 st line chemotherapy provides a
significant survival benefit for advanced colorectal cancer, the magnitudes of both …

Purpose To evaluate the efficacy and safety of bevacizumab when added to first-line
oxaliplatin-based chemotherapy (either capecitabine plus oxaliplatin [XELOX] or …

Background Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the
second leading cause of neoplasm-related death in the United States. Several studies …

Purpose Bevacizumab has demonstrated survival benefit in metastatic colorectal cancer
(mCRC) patients when combined with chemotherapy. Several randomized clinical studies …

Background This systematic review and meta-analysis aims to evaluate the additive effect of
bevacizumab when combined with first-line chemotherapy in metastatic colorectal cancer …

The BEBYP trial is a prospective, randomized, open-label, multicenter, phase III study
evaluating the continuation or reintroduction of bevacizumab with second-line …